Skip to main content
Top

Cancer and Metastasis Reviews

Issue 1/2023

Tumor Dormancy, Drug Resistance, Cancer Metastasis and Disease Recurrence

Content (21 Articles)

Preface

David A. Gewirtz

COMMENTARY

Tumor dormancy and disease recurrence

James L. Kirkland

Open Access Metastasis

Dormant cancer cells: programmed quiescence, senescence, or both?

Kevin Truskowski, Sarah R. Amend, Kenneth J. Pienta

Open Access Metastasis

Involvement of redox signalling in tumour cell dormancy and metastasis

Beatriz Puente-Cobacho, Alfonso Varela-López, José L. Quiles, Laura Vera-Ramirez

Role of myeloid-derived suppressor cells in tumor recurrence

Kathryn Cole, Zaid Al-Kadhimi, James E. Talmadge

Could senescence phenotypes strike the balance to promote tumor dormancy?

Fang-Yen Chiu, Raegan M. Kvadas, Zeinab Mheidly, Ashkan Shahbandi, James G. Jackson

Open Access

Dormancy, stemness, and therapy resistance: interconnected players in cancer evolution

Federica Francescangeli, Maria Laura De Angelis, Rachele Rossi, Adriano Cuccu, Alessandro Giuliani, Ruggero De Maria, Ann Zeuner

Autophagy, molecular chaperones, and unfolded protein response as promoters of tumor recurrence

Bashar Alhasan, Marina Mikeladze, Irina Guzhova, Boris Margulis

Chronic Lymphocytic Leukemia Non-Thematic Review

Mesenchymal stromal cell senescence in haematological malignancies

Natalya Plakhova, Vasilios Panagopoulos, Kate Vandyke, Andrew C. W. Zannettino, Krzysztof M. Mrozik

Open Access Melanoma Non-Thematic Review

Newly identified form of phenotypic plasticity of cancer: immunogenic mimicry

József Tímár, Kenneth V. Honn, Mary J. C. Hendrix, György Marko-Varga, Sirpa Jalkanen

Open Access Non-Thematic Review

The genetic profile and molecular subtypes of human pseudomyxoma peritonei and appendiceal mucinous neoplasms: a systematic review

Nora Wangari Murage, Nada Mabrouk Ahmed, Timothy J. Underwood, Zoë S. Walters, Stella Panagio Breininger

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine